Gemini Therapeutics (NASDAQ:GMTX) sets new 12-month high at $48.09

Gemini Therapeutics, Inc. share price. (NASDAQ:GMTX – Get Free Report ) hit a new 52-week high during trading on Monday . The company traded as high as $48.09 and last traded at $46.95, with a volume of 294367 shares traded. Shares previously closed at $48.11.

Gemini Therapeutics stock down 2.4%

The firm has a market cap of $2.03 billion, a P/E ratio of -48.11 and a beta of -0.12. The company has a fifty day moving average of $47.11 and a 200 day moving average of $42.90.

Gemini Therapeutics Company Profile

(Get a free report)

Gemini Therapeutics, Inc, a clinical-stage precision medicine company, is engaged in the development of various therapeutic compounds for the treatment of genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat patients with dry AMD.

Further reading

Get news and reviews for Gemini Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gemini Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.